首页|沙库巴曲缬沙坦联合芪苈强心胶囊治疗慢性心力衰竭的临床研究

沙库巴曲缬沙坦联合芪苈强心胶囊治疗慢性心力衰竭的临床研究

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
目的:探讨沙库巴曲缬沙坦联合芪苈强心胶囊治疗慢性心力衰竭的疗效及对心功能、心肌纤维化指标、神经内分泌因子的影响.方法:选取 2021 年 1 月～2022 年 12 月在鹤壁市人民医院心血管内科就诊的 94 例慢性心力衰竭患者作为研究对象,按随机数字表法分为对照组和观察组,各 47 例.对照组口服沙库巴曲缬沙坦,观察组在对照组治疗基础上增加口服芪苈强心胶囊.两组均治疗 8 w.比较治疗前和治疗 8 w 后两组心力衰竭患者Lee氏心衰积分、6 min步行距离、明尼苏达生活质量积分(Minnesota living with heart failure questionnaire,MLHFQ)、患者心功能指标水平、心肌纤维化指标水平、神经内分泌因子水平.比较两组临床疗效.结果:治疗 8 w后,观察组心力衰竭患者总有效率明显高于对照组(P＜0.05);两组 Lee 氏心衰积分、MLHFQ积分、左心室收缩末期内径(Left ventricular end-systolic diameter,LVESD)、左心室舒张末期内径(Left ventricular end-diastolic diameter,LVEDD)、半乳糖凝集素-3(Recombinant human Calectin-3,Calectin-3)、III型胶原前肽(Propeptide collagen III,PCIII)、可溶性 ST2(Soluble ST2,sST2)、肾素活性(Plasma renin activity,PRA)、N末端脑钠肽前体(N-Terminal pro-brain natriuretic peptide,NT-proBNP)和B型利钠肽(Brain natriuretic peptide,BNP)水平均明显降低,且观察组明显低于对照组(P＜0.05);两组 6 min步行距离、左心室射血分(Left ventricular ejection fraction,LVEF)水平明显增加,且观察组明显高于对照组(P＜0.05).结论:沙库巴曲缬沙坦联合芪苈强心胶囊可明显缓解慢性心力衰竭患者的临床症状,改善其心功能、心肌纤维化指标、神经内分泌因子水平.
Clinical study on the treatment of chronic heart failure with Sacubitril/Valsartan combined with Qili Qiangxin Capsules
Objective:To explore the efficacy of Sacubitril/Valsartan combined with Qili Qiangxin Capsules on chronic heart failure and its impact on cardiac function,myocardial fibrosis indexes and neuroendocrine factors.Methods:A total of 94 cases with heart failure treated in Hebi People's Hospital from January 2021 to December 2022 were selected as research objects.They were randomly divided into the control group and the observation group,47 cases in each group.The control group was given Sacubitril/Valsartan.The treatment group was added Qili Qiangxin Capsules on the basis of control group.The two groups were treated for 8 weeks.The Lee's heart failure score,6-min walking distance,and minnesota living with heart failure questionnaire(MLHFQ),cardiac function indexes,myocardial fibrosis indicators,neuroendocrine factors were compared in two groups before and after 8 weeks of treatment,respectively.The clinical efficacy of the two groups was compared.Results:After 8 weeks of treatment,the total effective rate of heart failure patients was 95.7%in observation group higher than that 76.6%in control group(P<0.05).After 8 weeks of treatment,the Lee's heart failure score,MLHFQ score,left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),recombinant human Calectin-3(Calectin-3),propeptide collagen III(PCIII),soluble ST2(sST2),brain natriuretic peptide(BNP),plasma renin activity(PRA),N-Terminal pro-brain natriuretic peptide(NT-proBNP)were decreased in two groups,and the observation group was significantly lower than the control group(P<0.05).The 6-min walking distance,left ventricular ejection fraction(LVEF)was increased in two groups,and the observation group was significantly higher than the control group(P<0.05).Conclusions:Sacubitril/Valsartan combined with Qili Qiangxin Capsules can significantly alleviate the clinical symptoms of chronic heart failure patients,improve cardiac function,myocardial fibrosis indicators,neuroendocrine factors.

Sacubitril/ValsartanQili Qiangxin CapsulesChronic heart failureCardiac function

刘净文、侯艳艳、杨楠、张南南、张素平、秦英华

展开 >

鹤壁市人民医院心血管内科,河南 鹤壁 458000

沙库巴曲缬沙坦 芪苈强心胶囊 慢性心力衰竭 心功能

河南省医学科技攻关计划联合共建项目

LHGJ20190052

2024

四川生理科学杂志
四川省生理科学会

四川生理科学杂志

影响因子：0.575
ISSN：1671-3885
年,卷(期)：2024.46(2)
  • 24